Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Novel Humanized Animal Model Reveals Clonal Architecture and Therapeutic Vulnerabilities in Myelofibrosis

Hamza Celik, PhD, Ethan Krug, Hassan Bjeije, PhD, Nancy Issa, MD, Wentao Han, Won Kyun Koh, Ruochao CZ Zhang, PhD, Maggie J. Allen, Terrence N Wong, MD PhD, Daniel AC Fisher, PhD, Tiandao Li, Stephen T. Oh, MD PhD, Grant A. Challen, PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-143034

Published: 2020

Journal Articles

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Naval G. Daver, MD, Marina Kremyanskaya, MD PhD, Casey O'Connell, MD, Kim-Hien Dao, DO,PhD, Stephen T Oh, MD PhD, Aaron T. Gerds, MDMS, Srdan Verstovsek, MD PhD, Sue Erickson-Viitanen, PhD, Feng Zhou, Albert Assad, MD, Abdulraheem Yacoub, MD

Blood (2018) 132 (Supplement 1): 353.

https://doi.org/10.1182/blood-2018-99-111338

Published: 2018

Journal Articles

Young Versus Old Age at Diagnosis Confers Distinct Genomic Profiles in Patients with Polycythemia Vera

Jared S Fowles, PhD, Chi-Joan How, MD, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 4322.

https://doi.org/10.1182/blood-2018-99-111573

Published: 2018

Journal Articles

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Stephen T Oh, MD PhD, Moshe Talpaz, MD, Aaron T. Gerds, MDMS, Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ruben A. Mesa, MD FACP, Carole Brennan Miller, MD, Candido E. Rivera, MD, Angela Fleischman, MD PhD, Swati Goel, Mark L Heaney, MD PhD, Casey O'Connell, MD, Murat Arcasoy, MD, Yafeng Zhang, PhD MD, Jun Kawashima, MD, Tomas Ganz, MD PhD, Carrie Baker Brachmann

Blood (2018) 132 (Supplement 1): 4282.

https://doi.org/10.1182/blood-2018-99-111349

Published: 2018

Journal Articles

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Daniel A.C. Fisher, PhD, Cathrine Miner, Elizabeth Engle, PhD, Hengrui Hu, Taylor B. Collins, Amy Zhou, MD, Maggie J. Allen, Olga Malkova, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 3062.

https://doi.org/10.1182/blood-2018-99-119022

Published: 2018

Journal Articles

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Kim-Hien Dao, DO,PhD, Robert H. Collins, MD, Jorge E. Cortes, MD, Michael W. Deininger, MD PhD, Brian J. Druker, MD, Jason R. Gotlib, MDMS, Tara Alyson Macey, PhD, Stephen T Oh, MD PhD, Jeffrey W. Tyner, PhD, Elliott F. Winton, MD

Blood (2018) 132 (Supplement 1): 350.

https://doi.org/10.1182/blood-2018-99-119476

Published: 2018

Journal Articles

Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib

Amy Zhou, MD, Maggie J. Allen, Mary Fulbright, Jared S Fowles, PhD, Daniel A.C. Fisher, PhD, Stephen T Oh, MD PhD

Blood (2018) 132 (Supplement 1): 1760.

https://doi.org/10.1182/blood-2018-99-113661

Published: 2018

Journal Articles

A Novel CSF3R Mutation Uncovers the Importance of Membrane-Proximal N-Glycosylation for Receptor Regulation

Seamus B Hughes, David Spiciarich, Richard D. Press, Sarah L Thompson, Jerald P. Radich, Carolyn Bertozzi, Stephen T. Oh, MD PhD, Julia E. Maxson, PhD

Blood (2016) 128 (22): 3141.

https://doi.org/10.1182/blood.V128.22.3141.3141

Published: 2016

Journal Articles

Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia

Stephen T. Oh, MD PhD, Christopher A. Miller, PhD, Yevgeniy Gindin, PhD, Taylor M. Brost, Jason Chan, MD PhD, Mary C. Fulbright, Daniel A.C. Fisher, PhD, Eric J. Duncavage, MD, Michelle O'Laughlin, Malachi Griffith, PhD, Obi L. Griffith, PhD, Lukas D. Wartman, MD

Blood (2016) 128 (22): 5496.

https://doi.org/10.1182/blood.V128.22.5496.5496

Published: 2016

Journal Articles

Mass Cytometry Analysis of Dysregulated Cytokine Production and Intracellular Signaling in Myelofibrosis

Daniel A.C. Fisher, PhD, Cathrine A. Miner, Elizabeth K. Engle, PhD, Taylor M. Brost, Olga Malkova, Stephen T. Oh, MD PhD

Blood (2016) 128 (22): 4277.

https://doi.org/10.1182/blood.V128.22.4277.4277

Published: 2016

Journal Articles

Identification of Functionally Primitive and Immunophenotypically Distinct Subpopulations in Secondary Acute Myeloid Leukemia By Mass Cytometry

Shovik Bandyopadhyay, Liyang Yu, Daniel A.C. Fisher, PhD, Olga Malkova, Stephen T. Oh, MD PhD

Blood (2016) 128 (22): 4278.

https://doi.org/10.1182/blood.V128.22.4278.4278

Published: 2016

Journal Articles

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Brady L. Stein, MD, Ahmad Naim, MD, Michael R. Grunwald, MD, Alison R. Moliterno, MD, Stephen T. Oh, MD PhD, Dilan Paranagama, PhD, Joseph A. Cordaro, PharmD, MBA, Hao Sun, MS, Shreekant Parasuraman, BPharm, PhD, Ralph V. Boccia, Ruben Mesa, MD FACP

Blood (2016) 128 (22): 1934.

https://doi.org/10.1182/blood.V128.22.1934.1934

Published: 2016

Journal Articles

Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in Myeloproliferative Neoplasms

Daniel A.C. Fisher, PhD, Olga Malkova, Mary C. Fulbright, Gregory K. Behbehani, MD PhD, Garry P. Nolan, PhD, Stephen T. Oh, MD PhD

Blood (2014) 124 (21): 1884.

https://doi.org/10.1182/blood.V124.21.1884.1884

Published: 2014

Journal Articles

Clinical Significance of LNK (SH2B3) Expression in Pediatric B Cell Precursor Acute Lymphoblastic Leukemia

Mio Yano, MD, Toshihiko Imamura, MD, Kenichi Sakamoto, MD, Daisuke Asai, MD, Gen Kano, MD, Hajime Hosoi, MD, Takao Deguchi, MD, Yoshiko Hashii, MD, Mikiya Endo, MD, Atsushi Sato, MD, Hirohide Kawasaki, MD, Yoshiyuki Kosaka, MD, Koji Kato, MDPhD, Hiroki Hori, MD, Keiko Yumura, MD, Junichi Hara, MD, Megumi Oda, MD, Stephen T. Oh, MD PhD, Keizo Horibe, MD

Blood (2014) 124 (21): 3772.

https://doi.org/10.1182/blood.V124.21.3772.3772

Published: 2014

Journal Articles

The JAK Inhibitor Ruxolitinib Elicits Hematologic and Symptomatic Improvement In Patients With Chuvash Polycythemia

Makiko Ban-Hoefen, MD, Elizabeth K. Engle, PhD, Eric M. Knoche, MD, Charu Kaiwar, Karyn Gordon, Deborah M. Moore, Stephen T. Oh, MD, PhD

Blood (2013) 122 (21): 4051.

https://doi.org/10.1182/blood.V122.21.4051.4051

Published: 2013

Journal Articles

Mass Cytometry Analysis Of Myelofibrosis and Secondary Acute Myeloid Leukemia Reveals Constitutive and Cytokine Induced Signaling Abnormalities With Differential Sensitivities To Ruxolitinib

Daniel A.C. Fisher, PhD, Gregory K. Behbehani, MD, PhD, Garry P. Nolan, PhD, Sean C. Bendall, PhD, Stephen T. Oh, MD, PhD

Blood (2013) 122 (21): 1610.

https://doi.org/10.1182/blood.V122.21.1610.1610

Published: 2013

Journal Articles

The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization

Blood (2013) 122 (21): 270.

https://doi.org/10.1182/blood.V122.21.270.270

Published: 2013

Journal Articles

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL -Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Eric M. Knoche, MD, Daniel A.C. Fisher, PhD, Gregory Rippberger, Li He, MS, BS, Deborah M. Moore, Jonathan L. Klein, MD, Stephen T. Oh, MD, PhD

Blood (2012) 120 (21): 2832.

https://doi.org/10.1182/blood.V120.21.2832.2832

Published: 2012

Journal Articles

Single Cell Mass Cytometry of Dysregulated Signaling Networks in Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia

Daniel A.C. Fisher, PhD, Erin F. Simonds, PhD, Gregory K. Behbehani, MD, PhD, Garry P. Nolan, PhD, Sean C. Bendall, PhD, Stephen T. Oh, MD, PhD

Blood (2012) 120 (21): 703.

https://doi.org/10.1182/blood.V120.21.703.703

Published: 2012

Journal Articles

Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia

Daniel A.C. Fisher, PhD, Christopher A. Miller, Michael D. McLellan, Robert S. Fulton, Katherine L. Martin, Charu Kaiwar, Deborah M. Moore, Timothy J. Ley, MD, Stephen T. Oh, MD, PhD

Blood (2012) 120 (21): 706.

https://doi.org/10.1182/blood.V120.21.706.706

Published: 2012

NARROW

A Novel Humanized Animal Model Reveals Clonal Architecture and Therapeutic Vulnerabilities in Myelofibrosis

A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

Young Versus Old Age at Diagnosis Confers Distinct Genomic Profiles in Patients with Polycythemia Vera

Hepcidin Suppression By Momelotinib Is Associated with Increased Iron Availability and Erythropoiesis in Transfusion-Dependent Myelofibrosis Patients

Aberrant Cytokine Production in Myelofibrosis Is Not Rectified By Ruxolitinib and Is Differentially Sensitive to Inhibition of JAK/STAT, MAP Kinase, and NFκB Signaling

Phase 2 Study of Ruxolitinib in Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia

Hepcidin Is Elevated in Primary and Secondary Myelofibrosis and Correlates with IL-6 and IL-2Rα but Is High in Patients Treated with Ruxolitinib

A Novel CSF3R Mutation Uncovers the Importance of Membrane-Proximal N-Glycosylation for Receptor Regulation

Clonal Evolution Revealed By Exome Sequencing in a Case of Primary Myelofibrosis Associated with Subsequent Development of Aggressive Systemic Mastocytosis/Mast Cell Leukemia

Mass Cytometry Analysis of Dysregulated Cytokine Production and Intracellular Signaling in Myelofibrosis

Identification of Functionally Primitive and Immunophenotypically Distinct Subpopulations in Secondary Acute Myeloid Leukemia By Mass Cytometry

Examining the Clinical Features and Underlying Cardiovascular Risk Among Patients with Polycythemia Vera in the REVEAL Study

Single Cell Mass Cytometry Reveals Hyperactivated Signaling Networks in Myeloproliferative Neoplasms

Clinical Significance of LNK (SH2B3) Expression in Pediatric B Cell Precursor Acute Lymphoblastic Leukemia

The JAK Inhibitor Ruxolitinib Elicits Hematologic and Symptomatic Improvement In Patients With Chuvash Polycythemia

Mass Cytometry Analysis Of Myelofibrosis and Secondary Acute Myeloid Leukemia Reveals Constitutive and Cytokine Induced Signaling Abnormalities With Differential Sensitivities To Ruxolitinib

The CSF3R T618I Mutation Found In Chronic Neutrophilic Leukemia Removes An O-Linked Glycosylation Site and Increases Receptor Dimerization

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL -Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Single Cell Mass Cytometry of Dysregulated Signaling Networks in Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia

Clonal Evolution Revealed by Whole Genome Sequencing in a Case of Primary Myelofibrosis Transformed to Secondary Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only